A $2.4 million acquisition will give Lineage Cell Therapeutics access to NeuroAirmid Therapeutics and its HUNT1 neural cell therapy program, which is being studied as a treatment for Huntington’s disease. The agreement also includes payments tied to the deal’s closing and to clinical, regulatory and commercial milestones.
NeuroAirmid has entered into a license agreement with The Regents of the University of California covering HUNT1. The program is currently in a Phase 1b/2a clinical study.
Lineage may pay up to $5.4 million on the first anniversary of the acquisition’s closing. It has also agreed to pay up to $48 million if HUNT1 reaches specified clinical development and regulatory milestones. Further payments to Lineage are due if it agrees to a sublicense or collaboration involving HUNT1, or if NeuroAirmid is sold.
In 2024, NeuroAirmid received an exclusive license from The Regents for neural stem cell compositions and methods to treat neurodegenerative disorders, as well as a nonexclusive license to related technology for developing and commercializing products for neurological diseases. NeuroAirmid has no employees and has not generated revenue.
Comments (0)
No comments yet. Be the first!